122 related articles for article (PubMed ID: 29415128)
21. Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13.
Drugs R D; 2006; 7(6):379-83. PubMed ID: 17073521
[TBL] [Abstract][Full Text] [Related]
22. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
23. Trends in net survival from ovarian cancer in six European Latin countries: results from the SUDCAN population-based study.
Chirlaque MD; Uhry Z; Salmerón D; Sánchez-Zapata MI; Zannoni GF; Navarro C;
Eur J Cancer Prev; 2017 Jan; 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study():S107-S113. PubMed ID: 28005613
[TBL] [Abstract][Full Text] [Related]
24. [The origin of informed consent].
Mallardi V
Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
[TBL] [Abstract][Full Text] [Related]
25. Patient-provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer.
Donovan HS; Hartenbach EM; Method MW
Gynecol Oncol; 2005 Nov; 99(2):404-11. PubMed ID: 16112174
[TBL] [Abstract][Full Text] [Related]
26. Profile of ovarian cancer patients seeking information from a web-based decision support program.
Markman M; Markman MR; Belland A; Petersen J
J Womens Health (Larchmt); 2006 Apr; 15(3):312-8. PubMed ID: 16620190
[TBL] [Abstract][Full Text] [Related]
27. Access to information and expectations of treatment decisions for prostate cancer patients--results of a European survey.
Tombal B; Baskin-Bey E; Schulman C
Eur J Cancer Care (Engl); 2013 Mar; 22(2):210-8. PubMed ID: 23320923
[TBL] [Abstract][Full Text] [Related]
28. PCA: prostate cancer, patient-centred approach or both?
Denis L; Joniau S; Bossi A; Baskin-Bey E; Fitzpatrick JM
BJU Int; 2012 Jul; 110(1):16-22. PubMed ID: 22233268
[TBL] [Abstract][Full Text] [Related]
29. Women's perceptions about treatment decision making for ovarian cancer.
Elit L; Charles C; Gold I; Gafni A; Farrell S; Tedford S; Dal Bello D; Whelan T
Gynecol Oncol; 2003 Feb; 88(2):89-95. PubMed ID: 12586585
[TBL] [Abstract][Full Text] [Related]
30. Patient-physician interactions during early breast-cancer treatment: results from an international online survey.
Lansdown M; Martin L; Fallowfield L
Curr Med Res Opin; 2008 Jul; 24(7):1891-904. PubMed ID: 18507893
[TBL] [Abstract][Full Text] [Related]
31. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
Chekerov R; Braicu I; Castillo-Tong DC; Richter R; Cadron I; Mahner S; Woelber L; Marth C; Van Gorp T; Speiser P; Zeillinger R; Vergote I; Sehouli J
Int J Gynecol Cancer; 2013 Feb; 23(2):268-75. PubMed ID: 23358178
[TBL] [Abstract][Full Text] [Related]
32. [Communication preferences of patients with prostate cancer : Preferences regarding the communication of bad news of patients with prostate cancer in Germany-results of an anonymous patient survey].
Merseburger AS; Kramer MW; Scheithe K; Colling C
Urologe A; 2016 Oct; 55(10):1339-1346. PubMed ID: 27306355
[TBL] [Abstract][Full Text] [Related]
33. A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer.
PEBC’s Ovarian Oncology Guidelines Group
Gynecol Oncol; 2017 Aug; 146(2):392-398. PubMed ID: 28601379
[TBL] [Abstract][Full Text] [Related]
34. Information needs and decisional preferences among women with ovarian cancer.
Stewart DE; Wong F; Cheung AM; Dancey J; Meana M; Cameron JI; McAndrews MP; Bunston T; Murphy J; Rosen B
Gynecol Oncol; 2000 Jun; 77(3):357-61. PubMed ID: 10831342
[TBL] [Abstract][Full Text] [Related]
35. A qualitative study of ovarian cancer survivors' perceptions of endpoints and goals of care.
Frey MK; Philips SR; Jeffries J; Herzberg AJ; Harding-Peets GL; Gordon JK; Bajada L; Ellis AE; Blank SV
Gynecol Oncol; 2014 Nov; 135(2):261-5. PubMed ID: 25230215
[TBL] [Abstract][Full Text] [Related]
36. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
37. Experiences and health care preferences of women with ovarian cancer during the diagnosis phase.
Jelicic L; Brooker J; Shand L; Knight T; Ricciardelli L; Denham G; Burney S
Psychooncology; 2019 Feb; 28(2):379-385. PubMed ID: 30485590
[TBL] [Abstract][Full Text] [Related]
38. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
Ray-Coquard I; Cibula D; Mirza MR; Reuss A; Ricci C; Colombo N; Koch H; Goffin F; González-Martin A; Ottevanger PB; Baumann K; Bjørge L; Lesoin A; Burges A; Rosenberg P; Gropp-Meier M; Harrela M; Harter P; Frenel JS; Minarik T; Pisano C; Hasenburg A; Merger M; du Bois A;
Int J Cancer; 2020 Jan; 146(2):439-448. PubMed ID: 31381147
[TBL] [Abstract][Full Text] [Related]
39. National differences in ulcerative colitis experience and management among patients from five European countries and Canada: an online survey.
Schreiber S; Panés J; Louis E; Holley D; Buch M; Paridaens K
J Crohns Colitis; 2013 Jul; 7(6):497-509. PubMed ID: 22921464
[TBL] [Abstract][Full Text] [Related]
40. Treatment preferences in recurrent ovarian cancer.
Donovan KA; Greene PG; Shuster JL; Partridge EE; Tucker DC
Gynecol Oncol; 2002 Aug; 86(2):200-11. PubMed ID: 12144829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
